Author: Rupsa Roy

Dalton’s Letter on Samsung Electronics Preferred Shares Featured in Yonhap Infomax Following a meeting with Samsung Electronics management in May, Dalton Investments sent a letter to the company’s board urging it to concentrate share buybacks on its preferred shares, which . . .

Dalton Korea’s Co-CEO Discusses Korea’s Value-Up Outlook in Maeil Business Interview As Dalton expands its investment in Korea, Song Ki-seok, Co-CEO of Dalton Korea, spoke with Maeil Business Newspaper about the outlook for the Korean stock market, including the growing . . .

Dalton Sends Statement to Samsung Electronics October 15, 2026 Dalton Investments, Inc. has sent a statement to the Board and management of Samsung Electronics Co., Ltd. In the statement, Dalton outlines its views regarding the allocation of capital between common . . .

Letter Sent to Bunka Shutter October 5, 2026 Rising Sun Management, an affiliate of Dalton Investments, has sent a letter to Bunka Shutter Co., Ltd. (“Bunka Shutter”). In the letter, we outline a shareholder proposal that we are considering submitting . . .

Letter Sent to Yakult Honsha September 11, 2026 Dalton Investments has sent a letter to the Corporate Value Enhancement Committee of Yakult Honsha Co., Ltd. (“Yakult”). Yakult has established a Corporate Value Enhancement Committee and is currently undertaking a fundamental . . .

Rising Sun Management (RSM), an affiliate of Dalton Investments, has submitted a shareholder proposal to Bunka Shutter Co., Ltd. (“Bunka Shutter”) ahead of the company’s upcoming AGM in June 2026…

Glass Lewis Recommends Voting AGAINST Aska Pharmaceutical Holdings’ Proposal No. 11 June 15, 2026 Dalton Investments welcomes the recommendation by Glass Lewis & Co. (“Glass Lewis”), the independent proxy advisory firm, that shareholders vote AGAINST Proposal No. 11 at the . . .

Our Views on the Proposal by ASKA Pharmaceutical Holdings Co., Ltd. to Activate Countermeasures May 27, 2026 We and our joint holders (collectively, “we” or “us”) strongly oppose the conditional activation proposal (Proposal No. 11) targeting us, which ASKA Pharmaceutical . . .

Glass Lewis Recommends Vote AGAINST Bunka Shutter Proposal No. 4 Dalton Investments welcomes the recommendation by Glass Lewis & Co. (“Glass Lewis”), the independent proxy advisory firm, that shareholders vote AGAINST Proposal No. 4 at the 80th Annual General Meeting . . .

We and our joint holders (collectively, “we” or “us”) strongly oppose the conditional activation proposal (Proposal No. 11) targeting us, which ASKA Pharmaceutical Holdings Co., Ltd. (“ASKA Pharmaceutical” or the “Company”) announced…